KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Short term Debt (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Short term Debt data on record, last reported at $1.0 billion in Q4 2025.

  • For Q4 2025, Short term Debt rose 3222.27% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $1.0 billion, up 3222.27%, while the annual FY2025 figure was $1.0 billion, 3222.27% up from the prior year.
  • Short term Debt reached $1.0 billion in Q4 2025 per JAZZ's latest filing, roughly flat from $1.0 billion in the prior quarter.
  • Across five years, Short term Debt topped out at $1.0 billion in Q4 2025 and bottomed at $31.0 million in Q3 2021.
  • Average Short term Debt over 5 years is $408.9 million, with a median of $317.8 million recorded in 2021.
  • Peak YoY movement for Short term Debt: plummeted 94.88% in 2024, then skyrocketed 3222.27% in 2025.
  • A 5-year view of Short term Debt shows it stood at $31.0 million in 2021, then changed by 0.0% to $31.0 million in 2022, then surged by 1851.46% to $605.0 million in 2023, then tumbled by 94.88% to $31.0 million in 2024, then surged by 3222.27% to $1.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $1.0 billion in Q4 2025, $1.0 billion in Q3 2025, and $1.0 billion in Q2 2025.